KPCM
GSK icon

Kings Point Capital Management’s GSK GSK Stock Holding History

Kings Point Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-227
Closed -$12K – 343
2017
Q1 		$12K Buy
+227
New +$11.5K ﹤0.01% 334

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Kings Point Capital Management's GSK Position: Q2 2017 in Review

Kings Point Capital Management sold out of GSK (GSK) in Q2 2017, closing a stake of 227 shares — an estimated $12K sold.

Kings Point Capital Management first reported a position in GSK in Q1 2017 and held it in 1 quarter. The position peaked at $12K in Q1 2017. 779 funds tracked by Wall St. Rank hold GSK as of Q2 2017.

  • Kings Point Capital Management reported no remaining GSK position as of Q2 2017 after selling out during the quarter.
  • Kings Point Capital Management sold 227 GSK shares in Q2 2017, an estimated $12K.
  • Kings Point Capital Management first reported a position in GSK in Q1 2017 and held it in 1 quarter.
  • Kings Point Capital Management's GSK position peaked at $12K in Q1 2017.
  • 779 funds tracked by Wall St. Rank held GSK as of Q2 2017.

Based on Kings Point Capital Management's 13F filing for Q2 2017, filed 8 Aug 2017.